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espite mounting evidence to the contrary, current
pharmacological practices largely ignore or minimize indi-
vidual and cross-group variations, which often are
extremely sizable.Textbooks and package inserts provided
by pharmaceutical companies give a fairly narrow range
for dosing recommendations. Consequently, medications
prescribed in the clinical setting are way too little for some,
and grossly excessive for others.There are also currently
no rational guidelines for choosing one class or type of
medication over the other (eg, selective serotonin uptake
inhibitors [SSRIs] vs others). This approach of “one size
fits all” is often the reason for poor treatment response,
noncompliance, severe adverse effects, unnecessary hospi-
talization, and even mortality. Pharmacogenetics and phar-
macogenomics (PG) hold great potential for addressing
these issues. In fact, while the field continues to progress
with lightning speed, with much more valuable informa-
tion still forthcoming, a great deal is already known about
factors governing both the pharmacokinetics and pharma-
codynamics of many drugs, and the technology is largely
there to put these into clinical use.
A number of major obstacles are likely responsible for this
apparent discrepancy between the progress of PG on the
one hand, and its clinical application on the other.These
include (i) feasibility of incorporating PG input into clini-
cal decision-making, which might be termed clinical phar-
macogenomics (CPG), and the impact of such an approach
on clinical outcome; (ii) complexity and apparent “over-
abundance” of PG information vis-à-vis drug response; (iii)
inherent “inertia” hindering the “diffusion of innovation,”
and the need for incorporating PG approaches into med-
ical education; (iv) problems related to the “economy of
401
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Despite remarkable progress, pharmacotherapy in gen-
eral, including that for the treatment of depressive con-
ditions, has often ignored the magnitude and clinical sig-
nificance of the huge interindividual variations in
pharmacokinetics and pharmacodynamics, resulting in
poor compliance, suboptimal therapeutic effects, and
treatment resistance. Advances in pharmacogenomics
and computer modeling technologies hold promise for
achieving the goals of “individualized” (“personalized”)
medicine. However, the challenges for realizing such
goals remain substantial. These include the packaging
and interpretation of genotyping results, changes in
medical practice (innovation diffusion), and infrastruc-
tural, financing, ethical, and organizational issues related
to the use of new information.    
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:401-408.
scale;” and financial support for new approaches.
In the following article, we will briefly review the litera-
ture suggesting that CPG is feasible and clinically rele-
vant, and that depressed subjects treated with the CPG
approach will show significantly fewer side effects
(greater tolerability), greater treatment adherence, bet-
ter clinical outcome, and a lower rate of relapse. Such
data should be encouraging for medical educators and
policymakers in moving forward with the broad adapta-
tion of CPG as part of the standard of care, and the real-
ization of the goals of what have been generally called
“individualized” or “personalized” medicine.
The prevalence and impact 
of clinical depression
Extensive clinical and epidemiological data, accumulated
over the past several decades, consistently indicate that clin-
ically significant depression is a highly prevalent condition.
Using the Composite International Diagnostic Interview,
a revised structured clinical interview instrument derived
from the Diagnostic Interview Schedule, the National
Comorbidity Study found that up to 25% of the general
population in the US are at risk of developing DSM-III-R-
defined major depression at least once in their lifetime.1
Utilizing similarly sophisticated research designs and
assessment instruments, a number of well-designed studies
also have been conducted in other countries, ranging from
France to Korea.2 Together, these studies convincingly
demonstrate that depression is a worldwide phenomenon,
and is a serious public health problem in any society.3
Approximately 15% of the people who suffer from major
depression eventually end their lives with suicide,4 making
suicide one of the ten major causes of death in many coun-
tries in recent years. Recent studies have also demonstrated
that depression is frequently associated with significant
morbidity, mortality, and functional impairment, and often
incurs substantial financial costs to society comparable to,
or exceeding, many other relatively common medical prob-
lems such as hypertension or diabetes.5 In addition, recent
studies have shown that depression is a major risk factor
for other life-threatening medical conditions, such as heart
attacks, stroke, and cancers.6,7 Furthermore, although acute
depressive episodes are often time-limited, longitudinal fol-
low-up studies conducted in recent years revealed that
relapse often occurs, rendering the long-term outcome of
such a condition far more ominous. Remission is often
incomplete; many continue to suffer from subsyndromal
depressive conditions, which also have been shown to be
associated with significant functional disability.8,9
Current status of antidepressant treatment:
success and limitations
Since the 1950s, a large number of antidepressants (ADs)
have been developed, each with proven efficacy in well-
designed, placebo-controlled, randomized clinical trials.
Starting with the classical tricyclic antidepressants and
monoamine oxidase inhibitors, now clinicians also have
at their disposal a large array of newer antidepressants,
including the SSRIs and the serotonin-norepinephrine
reuptake inhibitors (SNRIs), as well as a number of other
“novel” antidepressants.These compounds, each with its
unique profile, together afford clinicians powerful tools
in their attempts to bring patients back from the brink of
despair. At the same time, the multiplicity and complex-
ity presented by these diverse agents represent a puzzling
challenge for clinicians both young and seasoned.
Despite decades of research, it remains unclear why,
despite their proven efficacy (with proven superiority
compared with placebos), a relatively large proportion of
the patients fail to respond to these agents, and why dif-
ferent patients might respond to different agents. In other
words, there is at present no reliable method for clini-
cians to predict, prior to the initiation of treatment, which
of the several dozens of ADs might be the best for any
particular patient. This plight is further worsened by the
fact that there is a significant lag time, up to 4 to 6 weeks,
before the full benefit of the medication can be deter-
mined.Thus, for each “failed” treatment, substantive and
perhaps critical time is lost, which might lead to dire con-
sequence including further deterioration, dropping out,
and a further increase of the risk for mortality.
Similarly, clinicians currently have little means for deter-
mining the optimal starting dose of any of the ADs being
prescribed.This is so despite the fact that huge interindi-
vidual variations (up to 100 times) have been demon-
strated for most, if not all, ADs (and most of the other
medications). For a substantive proportion of the patients,
the “standard” initial doses (as suggested in package
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Selected abbreviations and acronyms
AD antidepressant
CYP cytochrome P-450 enzyme
PG pharmacogenetics and pharmacogenomics
SSRI selective serotonin reuptake inhibitor
inserts and in textbooks) represent only a small fraction of
the optimal dose needed for therapeutic response, for oth-
ers, such doses lead to severe side effects.The titration is
essentially “trial and error,” time-consuming, and con-
tributes further to the delay in treatment response and
recovery.Although the determination of the concentration
of drugs and their metabolites in bodily fluids (typically
plasma or serum) could be useful in this regard, it is usu-
ally not available in clinical settings (it may not be feasible
to have “blood level” measurements of various ADs avail-
able on a routine basis), and is typically done at steady-
state, requiring patients to be on a particular medication
for at an extended period of time before the measurement
(single dose kinetics is even harder to do and more diffi-
cult to interpret in the clinical settings).
Thus, although ADs are efficacious, neither their choice
nor the dosing strategy are based on rational principles,
leading to substantial “false starts,” delay in response,
diminished medication adherence, “under- or overtreat-
ment,” iatrogenic problems, morbidity, and even mortality.
The promise of pharmacogenetics/
pharmacogenomics
In such a context, it may be particularly surprising that
knowledge derived from the field of
pharmacogenetics/pharmacogenomics has not yet made
inroads into enhancing clinicians’ ability to “individual-
ize” or “personalize” pharmacotherapy. Evolving over
the past half century, the field of pharmacogenetics has
provided the basis for our understanding of many “idio-
syncratic” drug reactions. In recent years, it elucidated
much of the genetic basis of individual variations in phar-
macokinetics (especially genes determining drug metab-
olism) and pharmacodynamics (therapeutic target
responses). Their relevance for ADs is summarized
below.
Genes encoding enzymes and other protein products
responsible for the fate and disposition of 
psychotropics (pharmacokinetics) 
As is true with many other pharmacological agents, the
biotransformation of practically all ADs are primarily
mediated by a group of enzymes called cytochrome P-450
enzymes (CYPs) including CYP2D6, CYP2C19, CYP3A,
and CYP1A2. Huge individual variations in the activities
of these enzymes have long been demonstrated, much of
which have been accounted for with specific allelic varia-
tions in the genes encoding these enzymes. For example,
CYP2D6 allelic profiles determine whether a particular
individual is a poor metabolizer (those with defective
genes encoding no enzyme; approximately 2% in Han
Chinese and 7% in Caucasians), intermediate metabolizer
(those with “less effective” gene; approximately 50% in
East Asians), extensive metabolizer (those with “wild-
type” alleles; approximately 47% in East Asians) and
ultrarapid metabolizer (those with gene duplication or
multiplication; about 1% in East Asians and Northern
Europeans, but up to 7% in Spaniards and up to 30% in
Arabs and Ethiopians).10 Studies involving desipramine
and venlafaxine clearly indicate that these CYP2D6 poly-
morphisms are mainly responsible for the pharmacokinet-
ics, dosing, and side-effect profiles of these CYP2D6 sub-
strates.11,12 Similarly, specific allelic alterations also have
been demonstrated to determine CYP2C19 enzyme activ-
ities, and consequently the dosing and side effect profiles
of medications metabolized by this enzyme. In addition,
the activity of some of these CYPs also could be signifi-
cantly altered by exposure to environmental agents, whose
mechanisms also have been elucidated. For example, the
induction effect of St John’s wort (and other natural sub-
stances) on CYP3A4 is now known to be mediated via the
steroid and xenobiotic receptor [SXR], and the induction
of CYP1A2 by constituents of cigarettes is mediated
through the activation of the Ah receptor.13
Although less well documented, a number of genes other
than the CYPs also influence the process of pharmaco-
kinetics, and thus are likely to also affect the dosing and
side-effect profiles of ADs. These include genes encod-
ing transferases, such as glutathione-S-transferase (GST)
and UDP-glucurunosyltransferases (UGTs), which are
responsible for drug conjugation; multidrug-resistance
gene (MDR1) encoding the P-glycoprotein responsible
for exporting lipophilic compounds to the extracellular
space (and thus reducing drug absorption in the gut as
well as inhibiting their crossing the blood-brain bar-
rier)14,15; and, orosomucoid 1 and 2 (ORM1 and ORM2)
encoding the alpha-1-acid glycoproteins responsible for
most of the often extensive binding of psychotropics to
plasma proteins.16,17 (Table I)
Genes encoding therapeutic targets of ADs 
(pharmacodynamics) 
A number of monoamine neurotransmitter systems,
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including serotonin (5-HT), norepinephrine (NE), and
dopamine (DA), may all play crucial roles in mediating
vulnerability to depressive disorders.18-20 Moreover, most
of the commonly prescribed antidepressants are
believed to exert their effects at least in part through
the modulation of either the 5-HT or the NE systems,
or both.19,20 As the proximal site of action of many anti-
depressants in clinical use, the genes of the 5-HT, NE,
and DA systems therefore represent attractive func-
tional candidates in exploring antidepressant response.
Each of these systems is influenced by three types of
gene products: (i) those involved in biosynthesis and
catabolism of the monoamines; (ii) the receptors medi-
ating their effects; and (iii) the specific transporters
which remove them from the synapses.18 Although a
large number of studies have been conducted examin-
ing the association between many of these genes and
antidepressant response as well as risk for mood and
associated disorders, results have often been inconsis-
tent. Of these, however, the serotonin transporter
(SERT or 5-HTT) appears most promising. As the tar-
get of SSRIs, 5-HTT clearly plays a crucial role in deter-
mining patients’ response to these antidepressants, and
thus it is reasonable to speculate that functional genetic
polymorphism(s) should bear clinical relevance. This
indeed appears to be the case with the 5-HTT gene-
linked polymorphic region (5-HTTLPR), a 44 base-pair
insertion/deletion in the promoter region, which signif-
icantly influences the basal transcriptional activity of 5-
HTT,21 resulting in differential 5-HTT expression and 5-
HT cellular uptake.22 Hariri et al23 reported that subjects
who are homozygotic for the l allele for 5-HTTLPR
showed less fear and anxiety-related behaviors and
exhibited less amygdala neuronal activity as assessed by
functional magnetic resonance imaging in response to
fearful stimuli. In congruence with this, a large number
of studies have suggested association between this poly-
morphism and anxiety, depression and suicide risks. The
relationship between 5-HTTLPR polymorphisms and
antidepressant response has been intriguing. Seven of
nine studies,24-32 including one from Taiwan,24 showed
that the 5-HTTLPR l allele is associated with better or
more rapid SSRI response. Two recent studies also
implicate the 5-HTTLPR s allele in SSRI-emergent
adverse effects.33,34
Other genes that have been the target of similar inves-
tigations include serotonin2A receptor (5-HT2A),
35-38
dopamine transporter (DAT1),39-46 dopamine D2, D3, D4
receptor (DRD2, DRD3, DRD4), norepinephrine trans-
porter (NET), adrenalin2A receptor (ADRA2A),
47-50 beta
adrenalin receptor (betaARs),51 Catechol-O-methyltrans-
ferase (COMT),52 monoamine oxidase (MAO),53-55 tryp-
tophan hydroxylase (TPH),27,56,57 G-protein beta3-subunit
(Gbeta3),58 apolipoprotein E epsilon459 and brain-derived
neurotrophic factor (BDNF).60 (Table II)
From pharmacogenomics to individualized 
medicine
The remarkable advances as described above notwith-
standing, the goal of achieving “individualized medicine”
remains elusive. Although part of this apparent lack of
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Public Database SNPs
Gene Gene Chromosomal Size (bp)* # SNPs Mean distance between
name location SNPs (kb)
Cytochrome P450 1A2 CYP1A2 15q24.1 7776 28 0.6
Cytochrome P450 2C19C CYP2C19 10q23.33 90209 31 3.2
Cytochrome P450 2D6 CYP2D6 22q13.1 14797 125 0.1
Cytochrome P450 3A4 CYP3A4 7q22.1 27205 66 0.7
Cytochrome P450 3A5 CYP3A5 7q22.1 31790 15 2.7
Constitutive androstane receptor CAR, NR1I3 1q21.3 8,511 28 0.3
Steroid and xenobiotic recepter SXR, NR1I2 3q12-q13.3 38,001 69 0.6
Orosomucoid 1 ORM1 9q32 3422 70 0.3
Orosomucoid 2 ORM2 9q32 3230 73 0.3
Multiple drug resistance 1 MDR1 7q21.1 209390 202 1.0
UDP-glycosyltransferase UGT2B7 4q13.2 16451 0 0
UDP-glycosyltransferase UGT2B15 4q13.2 23987 46 0.9
Table I. Candidate genes and corresponding single nucleotide polymorphism (SNP) densities (pharmacokinetics).
progress in the clinical application of pharmacogenomics
may be attributable to existing gaps in the knowledge
base, there is a general belief that the field has progressed
to a point that sufficient information has already been
accumulated that is clinically applicable. Factors imped-
ing the progress in this direction have to do with infra-
structure as well as data showing efficacy and cost-effec-
tiveness of the pharmacogenomic approach.
Development of pharmacogenomic panel(s)
Although for some drug-metabolizing enzymes, such as
CYP2D6 and CYP2C19, allelic variations could lead to
dramatic functional and health consequences, in the
majority of the “candidate genes” for antidepressant
response, the influence is partial and may be cumula-
tive. This means that many genes may influence treat-
ment response, but each with only a small effect. This
is especially true with genes encoding potential thera-
peutic targets. Although this has been the consensus in
the field for a number of years, the extant pharmaco-
genetic literature is predominantly based on single
genotype or a combination of only a few genotypes. In
order for pharmacogenetic data to be clinically useful,
multiple relevant genotypes need to be tested simulta-
neously, and the results need to be available for clini-
cians in a timely manner (preferably within 24 hours),
such that the data could be included in the clinical deci-
sions made prior to the initiation of pharmacotherapy.
With the advent of high-throughput genotyping tech-
nologies, this is no longer out of reach. Thus, the next
generation of pharmacogenomic research should
include the development of specific pharmacogenomic
panel(s) for different disease categories and treatment
methods.
Developing user-friendly tools for interpreting 
pharmacogenomic results
Since for any disease/treatment category, such a panel
will likely include a large number of “candidate genes,”
whose function likely is influenced by multiple alleles,
the results of the panel will be exceedingly complex and
may not be easily interpretable by typical clinicians,
much less readily incorporated into the clinical decision
making process. To solve such a problem, a number of
modeling programs have been developed. Of these, the
most promising appears to be the neural network model
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Public Database SNPs
Gene Gene Chromosomal Size (bp)* # SNPs* Mean distance between
name location SNPs (kb)*
5-HT genes
* Serotonin 1A receptor HTR1A 5q12.3 1269 12 0.8
* Serotonin 2A receptor HTR2A 13q14.2 62661 121 0.6
* Serotonin 2C receptor HTR2C Xq24 326074 147 2.3
* Serotonin transporter HTT SLC6A4 17q11.2 24118 33 1.1
* Tryptophan hydroxylase TPH 11p15.1 19772 53 0.8
NE/DA genes
* Monoamine oxidase A MAOA X-p11.3 70206 51 1.7
* Catechol-O-methyl transferase COMT 22q11.21 27135 91 0.4
* Adrenergic alpha2A receptor ADRA2A 10q25.2 3650 22 0.9
* Norepinephrine transporter NET1 SLC6A2 16q12.2 46031 122 0.5
* Dopamine D2 receptor iso l/s DRD2 11q23.2 65577 98 0.8
* Dopamine D3 receptor iso a-d DRD3 3q13.31 50200 73 0.9
* Dopamine D4 receptor DRD4 11p15.5 3400 20 0.6
* Dopamine D5 receptor DRD5 4p16.1 2032 48 0.4
* Dopamine transporter DAT SLC6A3 5p15.33 52637 337 0.2
Other novel loci (example)
* Brain-derived neurotrophic factor BDNF 11p14.1 42903 30 2.0
Table II. Candidate genes and corresponding single nucleotide polymorphism (SNP) densities (pharmacodynamics/signaling). 5-HT, serotonin; NE,
norepinephrine; DA, dopamine
or neural fuzzy model. Using such a model, relevant
genetic data as well as clinical, sociodemographic, and
lifestyle variables (past medication response history,
concurrent use of other medications, dietary practices,
and exposure to other drug-inducing or inhibiting
agents, such as cigarette smoking) could be simultane-
ously incorporated into the estimations for the proba-
bility of efficacy and dosing strategy for different med-
ications. Further, a unique feature of such a model is
that it is “trainable,” in that as additional relevant data
become available, they could be readily incorporated to
improve the prediction model.
Pilot intervention project for 
clinical pharmacogenomics
Once established, such a therapeutic management sys-
tem (pharmacogenomic panel and the interpreting tool)
should then be examined in a series of studies to system-
atically examine its feasibility, acceptability, effectiveness
and ultimately cost-effectiveness. Randomized controlled
trials could be designed with consenting subjects ran-
domly assigned to experimental (pharmacogenomically
informed) and control (decision based on best current
practice guidelines).
Conclusion
In the past decade, the field of pharmacogenomics has
exploded, resulting in a huge body of literature pointing
to its promising and imminent clinical application and the
realization of the goal of individualizing medical care.
That this has not yet taken place is in all likelihood much
less related to the incompleteness of information, but to
the absence of infrastructure such as the management
system discussed above, and consequently the kind of
intervention studies examining the clinical utility and cost
effectiveness of such an approach.While the more tradi-
tional association studies are still needed to further
expand our knowledge base, it is also timely that the field
starts to explore ways to package knowledge that is
already available, and examine their clinical application
in well-designed studies. This represents an initial effort
in this direction, with the goal of enhancing efficacy,
reducing iatrogenic casualties, relieving untoward effects
and suffering secondary to delayed treatment response,
and ultimately, saving of medical care costs.This may lead
to a major breakthrough in understanding with potential
for radically changing the way medicine is practiced. ❏
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Estrategia farmacogenómica para la terapia
antidepresiva personalizada
A pesar del notable progreso de la farmacoterapia en
general, incluyendo el tratamiento de la depresión, a
menudo se ha ignorado la magnitud y el significado
clínico de las enormes variaciones inter-individuales
en la farmacocinética y farmacodinámica, que favo-
recen una pobre adherencia, efectos terapéuticos
sub-óptimos y resistencia al tratamiento. Han sido sig-
nificativos los avances recientes en el campo de la far-
macogenómica. Las actividades de las principales
enzimas del citocromo P-450, incluyendo CYP2D6,
CYP2C19, CYP3A4 y CYP1A2 han demostrado que
predicen las concentraciones séricas de antidepresi-
vos, la dosificación, los efectos secundarios y tanto las
interacciones fármaco-fármaco como fármaco-hierba,
y se han identificado los polimorfismos genéticos res-
ponsables de la expresión diferencial de estos genes.
Asimismo, los polimorfismos genéticos de las proteí-
nas responsables de mediar las respuestas de los anti-
depresivos, como el polimorfismo de la región pro-
motora del transportador de serotonina (5-HTTLPR),
han demostrado que determinan tanto las respues-
tas terapéuticas como la propensión a los efectos
secundarios. Tales avances, apoyados por las tecnolo-
gías de modelos computacionales, mantienen las pro-
mesas de alcanzar los objetivos de la medicina “indi-
vidualizada” (“personalizada”).  Sin embargo, los
desafíos para obtener tales objetivos siguen siendo
importantes. Estos incluyen la presentación e inter-
pretación de los resultados de la genotipificación, los
cambios en la práctica médica (difusión de la innova-
ción), temas de infraestructura, financieros, éticos y
organizacionales relacionados con el empleo de
nueva información.    
Stratégie pharmacogénomique pour l’indivi-
dualisation du traitement antidépresseur
Malgré des progrès remarquables, la pharmacothé-
rapie en général, dont celle des états dépressifs, a
souvent ignoré l’importance et la signification cli-
nique des importantesvariations interindividuelles de
la pharmacocinétique et de la pharmacodynamique,
conduisant à une observance médiocre, à des effets
thérapeutiques sous-optimaux et à une résistance au
traitement. Les récents progrès dans le domaine de
la pharmacogénomique ont été essentiels. Les acti-
vités des principales enzymes du cytochrome P-450,
dont les CYP2D6, CYP2C19, CYP3A4 et CYP1A2, ont
été montrées susceptibles de prédire les concentra-
tions sériques, le dosage, les effets indésirables et les
interactions médicament-médicament comme médi-
cament-plantes (phytothérapie) des antidépresseurs,
et des polymorphismes génétiques responsables de
l’expression différentielle de ces gènes ont été iden-
tifiés. De même, des polymorphismes génétiques des
protéines responsables de la médiation de l’effet des
antidépresseurs, tel que le polymorphisme de la
région promotrice du transporteur de la sérotonine
(5-HTTLPR), pourraient déterminer la réponse au trai-
tement ainsi que la propension aux effets indési-
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